


Amendments to the claims:

1. (Currently amended): A compound of Formula (I):



wherein R^1 represents H, halogen, or a group -YZ;

Y represents a bond (i.e. is absent), C_{1-6} alkylene or C_{2-6} alkenylene;


Z represents an aryl or heteroaryl group each comprising 5-14 ring members, said aryl or heteroaryl being optionally substituted by one or more substituents independently selected from halogen, OH, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, CN, C_{1-6} hydroxyalkyl, phenyl, O-(CH₂)₁₋₆-phenyl, NHSO₂R³, NHCOR³, CONR⁴R⁵, SO₂NR⁴R⁵;

R^3 , R^4 and R^5 independently represent H or C_{1-6} alkyl;


R^2 represents [~~H, halogen or~~] a group -Y¹Z¹;

Y¹ represents a bond (i.e. is absent), C_{1-6} alkylene, C_{2-6} alkenylene;

Z¹ represents a 6 membered heterocycle which is 4-piperidyl [~~6 membered aryl, 5 or 6 membered heteroaryl, 5 - 7 membered heterocyclyl, C₅₋₇-cycloalkyl, C₅₋₇-cycloalkenyl, each of~~] which may be optionally substituted by one or more substituents independently selected



from SO₂R⁶, NHSO₂R⁶, COR^7 , NR⁷R⁸, SO₂NR⁷R⁸, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, halogen, CONR⁷R⁸, NHCOR⁷, or phenyl (directly attached or attached by a C_{1-6} alkylene, CONH, C_{2-6} alkenylene spacer and optionally



substituted by one or more substituent selected from C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, OH, halogen);

R^6 represents H, C_{1-6} alkyl, $-(CH_2)_n$ phenyl or $-(CH_2)_n$ naphthyl (where n is 0 or 1 and each of which phenyl or naphthyl may be optionally substituted by one or more substituents independently selected from C_{1-6} alkyl, C_{1-6} alkoxy, halogen, NR^7R^8 , C_{1-6} haloalkyl, C_{1-6} haloalkoxy), CN or $-(O)_p$ phenyl (where p is 0 or 1 and the phenyl is optionally substituted by one or more substituents independently selected from halogen, C_{1-6} alkyl or C_{1-6} alkoxy));

R^7 and R^8 independently represents C_{1-6} alkyl, H, C_{1-6} alkylene NR^9R^{10} ; and

R^9 and R^{10} independently represents C_{1-6} alkyl, H;

~~[with the proviso R^1 and R^2 do not both represent H;]~~


or a pharmaceutically acceptable salt thereof.

2. (Original): A compound according to claim 1 wherein R^1 is YZ.

3. (Original): A compound according to claim 2 wherein Y is a bond or $-CH = CH-$.


4. (Original): A compound according to claim 3 wherein Y is a bond.

5. (Previously presented): A compound according to claim 1 wherein Z is phenyl (which may be unsubstituted or substituted once or twice by substituents independently selected from C_{1-3} alkoxy, CN, OH, phenyl, $-OCH_2$ phenyl $NHSO_2R^3$, $NHCO R^3$, $CONR^4R^5$, $SO_2NR^4R^5$, halogen, C_{1-3} hydroxyalkyl, C_{1-4} alkyl) or a heteroaryl group selected from



benzofuranyl, quinoliny, , pyrimidinyl, thiophenyl, isoxazolyl, pyridinyl (each of which may be optionally substituted by one or two groups independently selected from C_{1-3} alkyl, C_{1-3} alkoxy, halogen.

6. (Original): A compound according to claim 5 wherein Z is phenyl (which is unsubstituted or substituted once by a substituent selected from phenyl, OCH_2 phenyl, $NHSO_2CH_3$, $NHCOCH_3$, $CONH_2$, $CON(CH_3)_2$, Cl, F, OCH_3 , CN, OH, CH_2OH , CH_3 , $C(CH_3)_3$)



or a heterocyclic group selected from benzofuranyl, quinoliny, ,

pyrimidinyl, thiophenyl, benzothiophenyl, isoxazolyl, pyridinyl (each of which is substituted or is substituted once by a group selected from -OCH₃, CH₃, F).

7. (Original): A compound according to claim 6 wherein Z is phenyl (which is unsubstituted or substituted once by a substituent selected from phenyl, OCH₂ phenyl, NHSO₂CH₃, NHCOCH₃, CONH₂, CON(CH₃)₂, Cl, F, OCH₃, CN, OH, CH₂OH, CH₃, C(CH₃)₃).

8. (Original): A compound according to claim 7 wherein Z is phenyl.

Claims 9-10 (Cancelled)

11. (Currently amended): A compound according to claim 1, [claim 10] wherein Y¹ is a bond or C₁₋₃ alkylene.

12. (Withdrawn): A compound according to claim 10 wherein Z¹ is phenyl (unsubstituted or substituted by one substituent selected from NHSO₂R⁶, CONR⁷R⁸, CF₃, C₁₋₃ alkoxy, SO₂R⁶, NHCOR⁷, SO₂NR⁷R⁸, NR⁷R⁸) or a 6 membered heterocyclic group which contains one nitrogen atom (which is unsubstituted or substituted one time by a group selected from C₁₋₃ alkyl, CH₂ phenyl, SO₂R⁶, CONR⁷R⁸).

13. (Currently amended): A compound according to claim 1, [claim 12] wherein Z¹ is a 6 membered heterocycle which is 4-piperidyl substituted by SO₂R⁶.

Claims 14-18 (Cancelled)

19. (Previously presented): A pharmaceutical composition, comprising a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

Claims 20-22 (Cancelled)

23. (Withdrawn): A method of treating a disorder in a mammal, said disorder being mediated by inappropriate kinase activity, comprising administering to said mammal a compound as claimed in claim 1, or a salt, solvate, or a physiologically functional derivative thereof.

24. (Withdrawn): A method according to claim 23 wherein the inappropriate kinase activity is inappropriate IKK2 activity.

25. (Withdrawn): A method according to claim 24 wherein the disorder mediated by inappropriate IKK2 activity is inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease); osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultraviolet radiation (UV)-induced skin damage; autoimmune diseases including systemic lupus erythematosus, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, cancer, including Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including acquired immune deficiency syndrome (AIDS), adult respiratory distress syndrome, and Ataxia Telangiectasia, comprising administering a therapeutically effective amount to a mammal of a compound of formula (I), or a salt, solvate or pharmaceutically functional derivative thereof.

Claims 26-38 (Cancelled)

39. (New): A method of treating a disorder in a mammal, said disorder being mediated by inappropriate kinase activity, comprising administering to said mammal a compound as claimed in claim 1.

40. (New): A method according to claim 39 wherein the inappropriate kinase activity is inappropriate IKK2 activity.

41. (New): A method according to claim 40 wherein the disorder mediated by inappropriate IKK2 activity is inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease); osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultraviolet radiation (UV)-induced skin damage; autoimmune diseases including systemic lupus erythematosus, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, cancer, including Hodgkin's disease, cachexia, inflammation associated with infection and certain viral infections, including acquired immune deficiency syndrome (AIDS), adult respiratory distress syndrome,

Application No. 10/597,154
Group Art Unit: 1625

and Ataxia Telangiectasia, comprising administering a therapeutically effective amount to a mammal of a compound of formula (I), or a salt, solvate or pharmaceutically functional derivative thereof.